Impactul metforminului în tratamentul şi evoluţia pacienţilor oncologici cu diabet zaharat de tip 2

 The impact of metformin in the treatment and evolution of oncological patients with type 2 diabetes

First published: 27 octombrie 2017

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/OnHe.40.3.2017.1157


Metformin is an oral antidiabetic agent widely used in the treatment of type 2 diabetes mellitus, where it is commonly used as an insulin sensitizer since not only it has a function of lowering blood sugar, but also of reducing insulin resistance associated to hyperinsulinemia. It has been recently demonstrated that the use of metformin as an insulin sensitizer reduces incidence, progression and even mortality through cancer (Evans JM et al., 2005), while insulin and sulphonylureas have been associated with high incidence and mortality. Although the exact mechanism by which metformin has a protective role with respect to neoplasia is not precisely known, it has been established that its role of inhibiting cancerogenesis is due to its impact on the AMPK/LKB1 metabolism. A significant number of studies mention the beneficial effect that metformin has on the treatment and prognosis of certain neoplastic localizations (mammary, pancreas, colorectal, hepatic), most frequently by interfering with cell cycle regulation. Thus, the study of the effects of oral anti-diabetic drugs is worth being continued, as they can bring multiple benefits to administered oncological treatments. 

metformin, cancer, type II diabetes mellitus


Metforminul este un agent antidiabetic oral utilizat pe scară largă în tratamentul diabetului zaharat de tip 2, unde este utilizat în mod obișnuit ca agent de sensibilizare la insulină, deoarece nu numai că are o funcție de scădere a zahărului din sânge, ci și de reducere a hiperinsulinemiei asociate rezistenței la insulină. Recent, s-a demonstrat că utilizarea metforminului ca agent de sensibilizare la insulină reduce incidența, progresia și chiar mortalitatea prin cancer (Evans JM et al., 2005), în timp ce insulina și sulfonilureea au fost asociate cu incidență și mortalitate ridicate. Deși mecanismul exact prin care metforminul are un rol de protecție în ceea ce privește neoplazia nu este exact cunoscut, s-a stabilit că rolul său de inhibare a cancerogenezei se datorează im­pac­tului asupra metabolismului AMPK / LKB1. Un număr sem­ni­ficativ de studii menționează efectul benefic pe care met­forminul îl are asupra tratamentului și prognosticului anumitor localizări neoplazice (mamare, pancreas, colorectal, hepatic), cel mai frecvent prin interferența cu reglarea ciclului celular. Astfel, studiul efectelor medicamentelor antidiabetice orale merită să fie continuat, deoarece acestea pot aduce beneficii multiple tratamentelor oncologice administrate. 

Cancer and diabetes are on the list of the top 10 causes of global mortality, thus representing a real public health issue (WHO, 2011), which determines major costs for the population, both in terms of treatment expenditures and workforce shortages (ADA, 2008).
A significant number of cancers are attributed to the sedentary lifestyle that entails the early appearance of metabolic syndrome and insulin resistance, along with the onset of diabetes, cardiovascular disease and cancer. Hyperinsulinism negatively affects the prognosis of oncological patients and is an independent risk factor for several types of cancers, thus explaining the frequent association of obesity with neoplasia.
Insulin can promote cancerogenesis by the direct effect on epithelial tissues that act on the insulin receptor family (Belfiore et al., 2009) or indirectly by affecting the levels of other modulators such as IGF-1, sex hormones and adipokines (Wolf I. et al., 2005; Pollak M.N. et al., 2004). Recent evidence indicates that the abnormally high level of proliferative activity of premalignant and malignant cells requires high levels of nutrients to meet increased energy demand and protein biosynthesis demands (Vander Heiden M.G., 2009).
Following epidemiological studies, it was established that patients with type 2 diabetes have an increased risk of developing some types of solid and haematological malignancies, including non-Hodgkin’s lymphoma or bladder, endometrium, liver, pancreas, or mammary gland tumors - through hyperinsulinism and the mechanism of IGF 1 system activation (Pollak, 2008).
Metformin is a widely used oral antidiabetic agent in the treatment of type 2 diabetes mellitus, where it is commonly used as an insulin sensitizer since it has not only a function of lowering blood sugar, but also of reducing insulin resistance associated by hyperinsulinemia. This medicine acts as a growth inhibitor, rather than an insulin sensitizer with respect to epithelial cells (Zakikhani M. et al., 2006).
It has been recently demonstrated that the use of metformin as an insulin sensitizer reduces incidence, progression and even mortality through cancer (Evans J.M. et al., 2005), while insulin and sulphonylureas have been associated with high incidence and mortality.
Although the exact mechanism by which metformin has a protective role with respect to neoplasia is not precisely known, it has been established that its role of inhibiting cancerogenesis is due to its impact on the AMPK/LKB1 metabolism – either directly, by inhibiting the activation of adenosine monophosphate kinase, or indirectly, by lowering the level of insulin in the systemic circulation. Regarding the direct effects of metformin, LKB1, which is a downstream signaling molecule in the AMPK pathway, functions as a tumor suppressor protein (p. 53). Thus, AMPK-induced metformin activation could lead to increased LKB1-mediated tumor suppression which would directly inhibit cell proliferation and colony formation and promote partial cell cycle arrest in cancer cell lines (Alinova et al., 2009).
Metformin can exert similar antineoplastic effects through an indirect mechanism: metformin activates the AMPK pathway in hepatocytes and skeletal muscles. Thus, it inhibits hepatic gluconeogenesis and glucose efflux from skeletal muscles and consequently reduces circulating glucose and insulin concentrations, both contributing to cancerogenesis (Shaw R.J. et al., 2005).
Metformin is the first option in the treatment of type 2 diabetes mellitus, prescribed as a single agent for patients in the initial stage of the disease, or in combination with other oral antidiabetics in patients with advanced disease (Kowall B. et al., 2015). Metformin has been shown to reduce the incidence of type 2 diabetes in patients at high risk (Knowler W.C. et al., 2002) with beneficial effects for at least 10 years (Knowler W.C. et al., 2009). It is an inexpensive and well tolerated drug, whose side effects are very rare, which determine its widespread use.
The idea that the use of metformin is associated with a decrease in malignancy risk for certain organs can be explained by the fact that metformin works by using the nutrients needed to produce a new cell, starting from a proliferative cell (Vander Heiden M.G., 2009). Metformin appears to be associated with a decrease of cancer risk in the colon, pancreas and mammary gland, because diabetes or elevated blood glucose and insulin levels play an important role in the development of these types of tumors (Xue F., Michels K.B., 2007; Raimondi S. et al., 2009). Regarding colon cancer, it has been shown that metformin potentiates the effects of hypercaloric nutrition that stimulate tumor growth (Zakikhani M. et al, 2008).
In the case of mammary gland neoplasm, it was observed that diabetic patients treated with metformin had a higher rate of complete response to neoadjuvant chemotherapy than the patients treated with other types of antidiabetic agents. In patients differentiated by many variables - Body Mass Index, stage of the disease, degree of tumor differentiation, HER2 status, estrogen and progesterone receptors, age and use of neoadjuvant treatment with taxanes, metformin remained an independent predictor of the therapeutic response. The use of metformin was a much better predictor than certain tumor characteristics, including differentiation, hormone receptor status, or overexpression of HER2 neu (Goodwin P., Ligibel J., Stambolic Vuc, 2009).
Breast cancer cells can be protected against growth inhibition induced by metformin by diminishing RNA against AMP-kinase. This demonstrates that metformin-activated AMP-kinase, recently demonstrated to be necessary for the metformin inhibition of gluconeogenesis in hepatocytes, is also involved in the metformin-induced growth inhibition of epithelial cells (Zakikhani M. et al., 2006).
In the case of patients diagnosed with bronchopulmonary neoplasm, whose frequency is significant with associated type 2 diabetes mellitus, it has been shown that their response to treatment is influenced by metformin by increasing sensitivity to external irradiation, given that irradiation is a known inducer of AMPK, and metformin can modulate this effect, thus improving the response to radiotherapy. This hypothesis was tested using cell lines from the breast, lung and prostate. After confirming induction of AMPK in these cell lines with irradiation treatment independent of LKB1 status, induction of resistance to ionizing radiation by the AMPK inhibitor was demonstrated. It has also been demonstrated that metformin increases sensitivity to ionizing radiation, increase assessed by increasing the duration of irradiation after exposure to 2 Gy, supporting this hypothesis (Sanli T. et al., 2010).
According to some studies, in patients with non-small cell lung cancer and type 2 diabetes mellitus, chemotherapy in combination with metformin increased the survival rate compared to the same chemotherapy, but in combination with insulin or other oral anti-diabetic treatments (8.4 months for chemotherapy + metformin versus 4.7 months for chemotherapy + insulin versus 6.4 months for chemotherapy + other oral anti-diabetic) (Tan B. et al., 2011).
The use of metformin as a prevention and treatment agent of certain neoplastic locations has also gained considerable interest in hepatic neoplasms, due to the increased frequency of diabetes associated with this type of cancer. 
Some studies thus confirm the improvement in survival rate of patients with primitive hepatic neoplasms associated with type 2 diabetes and treated with metformin (Shu-Juan Ma et al., 2016).
A significant number of studies on pancreatic neoplasm and the treatment of type 2 diabetes discuss the effect that metformin has on inhibiting the cell proliferation, migration and invasion process by destroying neoplastic stem cells, intervening at the microRNA level. 
Oral administration of metformin in diabetic patients suffering from pancreatic neoplasm increased the prognosis of oncologic treatment in these patients. By its mode of action, in the case of the pancreas, metformin decreased the expression of neoplastic stem cell markers: CD 44, EpCAM, EZH2, Notch-1, Nanog and Oct4 (Bao B. et al., 2012). Studies in diabetic patients treated with different classes of oral antidiabetic agents have shown a lower risk of developing pancreatic adenocarcinoma if the anti-diabetic treatment was metformin (Yu-Yang, 2009).
Also, in the case of rectal neoplasm, as well as the aforementioned neoplastic localizations, the studies conducted so far associate the use of metformin with a low rate of appearance of this type of neoplasia. As well as for the bronchopulmonary neoplasm, the mechanism of action of metformin coincides with that from colorectal neoplasm. Metformin decreases AMPK, which is intended to activate the mTOR pathway that has been shown to influence cellular proliferation (Caroline Cao et al., 2014).
The study of metformin role as an oral antidiabetic in the management of neoplastic disease in patients with type 2 diabetes is particularly important and requires further consideration, given the studies that perpetuate the idea that metformin reduces inflammation and prevents cancer development, or potentiates oncological treatment where the oncological disease has already begun. 


1. ADA. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31(3):596–615.
2. Alimova IN et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8(6):909–15.
3. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009; 30: 586–623.
4. Bin Bao, Zhiwei Wang, Shadan Ali, Aamir Ahmad, Asfar S Azmi, Sanila, H Sarkar, Sanjeev Banerjee, Dejuan Kong, Yiwei Li, Shivam Thakur and Fazlul H Sarkar. Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells, doi: 10.1158/1940-6207.CAPR-11-0299, March 2012.
5. Bowker SL et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care 2006; 29(8):1990–1.
6. Caroline Yao, Guy F Nash, and Tamas Hickish. Management of colorectal cancer and diabetes, J R Soc Med. 2014 Mar; 107(3): 103–109. doi:  10.1177/0141076813512121
7. Evans JM et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330(7503):1304–5.
8. Goodwin P, Ligibel J, Stambolic Vuc. Metmorfin in breast cancer: time to action, Journal of Clinical Oncology 27, no. 20 (July 2009) 3271-3273, doi: 10.1200/JCO.2009.22.1630.
9. Kowall B, Rathmann W, Kostev K (2015). Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis. Diabetes Care, 38(1), 59–65.
10. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393–403.
11. Knowler WC, Fowler SE, Hamman RF, et al. Diabetes Prevention Program Research Group. 10-Year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet 2009; 374:1677–86.
12. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505–18.
13. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8(12):915–28.
14. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6: 699–708.
15. Mahvash Zakikhani, Ryan Dowling, I. George Fantus, Nahum Sonenberg and Michael Pollak. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells, doi: 10.1158/0008-5472.CAN-06-1500, November 2006.
16. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC et al. Ionizing radiation activates AMPactivated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat. Oncol. Biol. Phys. 2010; 78:221-9.
17. Shaw RJ et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310(5754):1642–6.
18. Shu-Juan Ma, Yi-Xiang Zheng, Peng-Cheng Zhou, Yan-Ni Xiao and Hong-Zhuan Tan, Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis, Oncotarget. 2016 Oct 4; 7(40): 66202–66211, Published online 2016 Aug 2. doi:  10.18632/oncotarget.11033.
19. Tan BX, Yao WX, Ge J, Peng XC, Du XB, Zhang R, Yao B, Xie K, Li LH, Dong H, Gao F, Zhao F, Hou JM, Su JM and Liu JY (2011). Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes Cancer, 117: 5103–5111. doi:10.1002/cncr.26151.
20. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029–33.
21. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J ClinNutr 2007; 86: s823–35.
22. Yu–Xiao Yang. Do Diabetes Drugs Modify the Risk of Pancreatic Cancer? Gastroenterology, Volume 137, Issue 2, August 2009, pages 412-5.
23. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP activated protein kinase. Cancer Prev Res (Phila) 2008; 1:369–75.
24. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6:103–11.
25. WHO, 2011. The top 10 causes of death, World Health Organization; accessed 30 July 2012

Articole din ediţiile anterioare

REVIEW | Ediţia 3 / 2016

Tratamentul tusei cronice în cadrul îngrijirilor paliative. O permanentă provocare

Cristina David

Impactul tusei asupra pacienţilor şi rudelor este adesea subestimat. Pacienţii pot necesita tratament simptomatic când tusea este persistentă sau l...

07 martie 2017

Tratamentul metronomic săptămânal cu carboplatin-paclitaxel în cancerul epitelial ovarian avansat pentru pacientele cu vârstă fragilă

Bogdana Ioana Nedejde

Vârsta înaintată a pacientelor diagnosticate cu cancer ovarian avansat prezintă un impact major asupra prognosticului, în­tru­cât tratamentul stand...

27 martie 2019
PREZENTARE DE CAZ | Ediţia 1 / 2016

Cancer pulmonar non-microcelular cu metastaze tiroidiene și de parotidă la diagnostic și remisiune completă după tratament. Prezentare

Dan Ilie-Damboiu, Alexandru C. Grigorescu

Cancerul pulmonar este a doua cea mai frecventă neoplazie şi prima cauză de deces asociată neoplaziilor atât la bărbaţi, cât şi la femei. În acest ...

25 aprilie 2017
CANCER DIAGNOSIS | Ediţia 4 49 / 2019

Evaluarea IRM multiparametrică în hiperplazia benignă de prostată – o adevărată provocare în excluderea cancerului de prostată

Sandra O. Jurcă, Gabriel Gluck, Ioana G. Lupescu

Evaluarea IRM multiparametrică este un instrument de ne­pre­ţuit în depistarea, localizarea şi caracterizarea le­ziu­nilor de prostată, una dintre ...

14 decembrie 2019